Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY518674 in Atherogenic Dyslipidemia
NCT00116519Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ly518674 in atherogenic dyslipidemia (AD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: High-Density Lipoprotein Cholesterol at 12 weeks, Triglycerides at 12 weeks and 1 more. Started Jul 2005; status: completed.
02
Drugs
ly518674
03
Conditions
atherogenic dyslipidemia (AD)
Beyond the preview
Go deeper on NCT00116519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00116519.